Procter & Gamble Health Ltd

The company maintains a strong liquidity position, with a current ratio of 2.44 and cash and equivalents of INR 898.1 million, indicating a solid ability to meet short-term obligations. The low debt-to-equity ratio of 0.01 suggests a conservative capital structure, with minimal reliance on long-term debt. This aligns with the industry preference for low leverage and strong equity positions. Profitability metrics show a return on equity of 43.66% and a return on assets of 29.52%, both significantly above the typical thresholds for pharmaceutical firms. The gross profit margin of 66.04% (calculated from revenue and gross profit) and an operating margin of 32.30% (calculated from operating income) further highlight the company's strong pricing power and cost control. The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. Geographically, the firm operates primarily in India, with no disclosed international revenue streams. This concentration may expose the company to regional economic and regulatory risks. The company's revenue growth is expected to remain stable, with no significant changes projected in the current or next fiscal year. Historical revenue of INR 9.34 billion provides a baseline for future performance, though the absence of growth drivers or new product launches in the data suggests a conservative outlook. Risk factors are minimal, with low liquidity and dilution risk scores. No immediate filing-based flags were detected, and the company's capital structure remains stable. The absence of dilution risk is supported by the identical basic and diluted share counts, indicating no near-term pressure from share issuance. Recent events include the latest financial filing (HA-latest), which provides the most recent snapshot of the company's financial position. No recent earnings call transcripts or regulatory filings were identified in the available data.